Abstract: A high-performance, low-cost modular cushion using range of novel dynamically responsive materials has been designed and developed for use in seating pressure relief. The use of individual contained spheres creates a localized area of gel to minimize both flattening under pressure, and inflating in areas without contact while the elastic nature of the polymers creates a durable system that recovers rapidly from deformation. Gel balls of varying densities have been developed to optimize performance. Quantification of individual ball mechanical properties has been completed which provides load-deflection curves to inform optimal ball array layout based on user interface pressure distributions. A fitting algorithm is proposed which will employ the patient's seating interface pressure distribution to design a personalized modular cushion layout which will evenly distribute contact pressure across seating support interface and maximize contact pressure area.

Abstract: A patient maneuvering apparatus including a substantially planar body having a top surface, a bottom surface opposing the top surface, a left end, and a right end. The patient maneuvering apparatus also includes a first handle disposed at the left end of the body and a second handle disposed at the right end of the body, a mesh layer with a mesh layer thickness at least partially defining the bottom surface, a fabric layer of an absorbent material at least partially defining the top surface and with a fabric layer thickness, and a border spanning the perimeter of the body, surrounding the mesh and fabric layers, and with a border thickness greater than the mesh layer thickness and the fabric layer thickness.

Abstract: A massage device includes a leg assembly that extends between a table top assembly and a surface. The leg assembly includes a first leg and a second leg that are coupled to one another. The first leg includes a first leg top that is coupled to the table top assembly, a first leg bottom that is positioned adjacent to the surface, and a first leg body that extends between the first leg top and the first leg bottom. The second leg includes a second leg top that is coupled to the table top assembly, a second leg bottom that is positioned adjacent to the surface, and a second leg body that extends between the second leg top and the second leg bottom. The second leg bottom includes a pair of fork members that are coupled to the second leg body, the fork members being positioned relative to one another to provide a pair of spaced apart contact points along the surface.

Abstract: Embodiments disclosed herein relate to a garment system including at least one muscle or at least one joint activity sensor, and at least one actuator that operates responsive to sensing feedback from the at least one muscle or the at least one joint activity sensor to cause a flexible compression garment to selectively compress against or selectively relieve compression against at least one body part of a subject. Embodiments disclosed herein also relate to methods of using such garment systems.

Abstract: An aid device for the movement and rehabilitation hand fingers includes a exoskeleton, an articulated glove or a wearable mechanism configured to be positioned on the back of at least one finger and to be mechanically constrained to the finger, and a motorized system exerting a movement or a change in the configuration of the exoskeleton. The exoskeleton includes a rigid elements arranged on a row one behind the other along a longitudinal axis parallel to the longitudinal extension of the finger and articulated with each other to make a modular underactuated structure and obtain maximum shape and kinematic adaptability to the fingers, particularly to follow the extension and flexing movement of the fingers. The motorized system includes pulling and/or pushing elements that act on one or more of the elements of the exoskeleton to produce finger movements and particularly the extension and flexing movements of the fingers.

Abstract: A massage device includes a main body, a vibrator, a control switch and a suction arrangement. The main body has a massaging portion, a handle portion, and a receiving cavity. The main body has an inwardly curved surface formed on the massaging portion. The vibrator is received in the receiving cavity at the massaging portion of the main body. The suction arrangement includes a guiding member and a suction pump. The guiding member is outwardly extended from the main body and has an air passage channel communicating the receiving cavity with ambient atmosphere. The suction pump is received in the receiving cavity for drawing air from the ambient atmosphere to the receiving cavity. The control switch is provided on the main body for selectively switching the vibrator and the suction pump.

Abstract: A robotic massage machine that includes at least one movable robotic arm having a first end effector, a processor that controls the movable robotic arm, a memory, a first body form having at least a first anatomical calibration point, a preprogrammed initial massage path based on the first body form, and a second body form having at least a first anatomical calibration point located in an analogous anatomical location as the first anatomical calibration point of the first body form. The processor is programmed to morph the initial massage path to calculate a calibrated massage path based on the second body form.

Abstract: Resuscitation devices for performing external chest compression (ECC) and defibrillation on a person and methods using the devices are disclosed. The disclosed devices can include chest compression members and a communication module that can communicate with a remote command center. The disclosed devices can also include an optional defibrillation module that may be integrated. The devices can be coupled to a backboard and can include physiological sensors, electrodes, wheels, controllers, human interface devices, cooling modules, ventilators, cameras, and voice output devices. Methods can include defibrillating, pacing, ventilating, cooling, and performing ECC in an integrated, coordinated, and/or synchronous manner using the full capabilities of the device. Some devices include controllers executing methods for automatically performing the coordinated activities utilizing the device capabilities.

Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.

Abstract: A technique is provided for suppressing discoloration of an aqueous composition containing a halogenated isoquinoline derivative during preservation at high temperature. A pharmaceutical preparation obtained by storing an aqueous composition comprising a compound represented by Formula (1), wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, in a container made of polyolefin-based resin.

Abstract: The invention provides a light-curable dental material comprising a polymerizable compound having at least one ethylenically unsaturated bond and a hexaaryl bisimidazole as a photopolymerisation initiator.

Abstract: The purpose of the present invention is to provide a stick cosmetic that has a stick shape and a novel function that allows said stick cosmetic to be used to replenish moisture throughout the day. The present invention relates to a stick cosmetic for moisture replenishment, said stick cosmetic comprising: (A) 0.01-50 mass % of a fluid volatile oil component; (B) 10 mass % or more of water; (C) a wax that is capable of gelating the fluid volatile oil component; (D) a silicone elastomer; and (E) a silicone-based surfactant. The cosmetic of the present invention preferably further comprises (F) a moisturizing agent. The cosmetic of the present invention is suitable for use in touching up makeup and has a stick shape that exhibits excellent portability.

Abstract: Provided are compositions and methods that are useful for hair care compositions. The compositions comprise polyurethane microparticles coated with zinc salt particles, wherein the ratio of zinc salt to polyurethane is in a range of from 1:99 to 3:7, and the polyurethane microparticles have an average particle size of less than 100 microns. Also provided are methods of preparation of such compositions.

Abstract: Zinc oxide coated with silicon oxide of the present invention is zinc oxide which is coated with silicon oxide wherein surfaces of zinc oxide particles are coated with silicon oxide coatings, and the coated zinc oxide particles comprises at least one element selected from a group consisting of Mg, Ca, and Ba.

Abstract: The present invention relates to a core-shell type polymer particle including a shell part composed of an amphoteric polymer (A) and a core part composed of a hydrophobic polymer (B).

Abstract: A composition for oxidatively treating hair includes—50-96 wt. % water; 0.5-20 wt. % hydrogen peroxide; at least one linear saturated 1-alkanol with 12-30 carbon atoms in a total volume of 2.7-6 wt. %; at least one polyethylene glycol ether of a linear saturated C12-C22 alkanol with 15-30 ethylene oxide units in the molecule, in a total volume of 0.3-1 wt. %; at least one anionic surfactant in a total volume of 0.3-1 wt. %; at least one cellulose ether in a total volume of 0.1-0.5 wt. %; and at least one oil in a total volume of 0.1-0.5 wt. %. The composition is highly suitable as an oxidant for powdered color preparations, containing oxidizing coloring intermediates and also pigments, which do not permanently change the color of the fibers, as well as, optionally, including solid inorganic alkalizing agents, as well as, optionally, ammonium salts, like ammonium chloride and ammonium sulfate, in particular with respect to the application properties of the application mixture.

Abstract: The present invention relates to the use of an aqueous or aqueous-alcoholic gel of synthetic phyllosilicate of formula Mg3Si4O10(OH)2 in a cosmetic composition. A cosmetic composition comprising such a gel and also cosmetic processes for caring for and/or making up the skin and/or the nails using such an aqueous or aqueous-alcoholic gel of synthetic phyllosilicate are also targeted.

Abstract: The present invention relates to a skin whitening cosmetic composition comprising verbenone as an active ingredient or a pharmaceutical composition for treating or preventing skin pigmentation disorders.

Abstract: The present invention relates to the cosmetic use of at least one compound of formula (I), of at least one of its salts of formula (II) or of a mixture comprising at least one compound of formula (I) and at least one compound of formula (II): as agent(s) intended to prevent and/or treat cutaneous signs of ageing, A non-therapeutic cosmetic method for preventing and/or treating cutaneous signs of ageing using these compounds is also targeted.

Abstract: The subject matter described herein is directed to sanitizing compositions comprising: i. an antimicrobial component comprising a mixture of a quaternary ammonium salt, e.g., benzalkonium chloride and/or benzethonium chloride, paraben and acetic acid in a ratio of about 1:0.8-1.3:1.6-2.5 (w:w:v); ii. a lower alkyl ketone; and iii. an emollient; and optionally, iv. a fragrance. Methods of using and making the compositions are described as well as articles of manufacture incorporating the compositions.

Abstract: Provided herein is an aqueous mouthwash formulation comprising a salt of an N?-acyl-L-arginine alkyl ester and a peroxide source. The mouthwash formulation provides anti-microbial activity and whitening activity.

Abstract: A low water tooth whitening composition containing a dye, a whiteness enhancing material, and an orally acceptable carrier vehicle.

Abstract: The disclosure relates to agents for dyeing keratin fibers, in particular human hair, containing, in a cosmetic carrier (a) at least one direct dye of formula (I), wherein Het1, Het2 represent cationic heterocycles; R1, R3 respectively represent a substitute which is not hydrogen, and Q represents a grouping of formula (VIII), (IX), or (X).

Abstract: The present disclosure relates to agents for dyeing keratin fibers, in particular human hair, containing, in a cosmetic carrier (a) at least one direct dye of formula (I), wherein Y1, Y2 independently represent a nitrogen atom or a group C—R9, and Q represents a special linker group of formula (II), (III), (IV) or (V), (b) at least one anionic surfactant and/or at least one cationic surfactant.

Abstract: The present invention simply and efficiently extracts and produces useful substances such as astaxanthin, silk proteins, and polyphenols from a plant material abundantly containing these useful substances. A material such as silk proteins or plant materials containing a useful substance is: immersed in an alkaline aqueous solution which is of a neutral salt and which is obtained by adding a proper amount of an alkaline agent to an aqueous solution of, for example, sodium chloride, calcium chloride, or the like; and reductively decomposed using the reduction potential generated on the alkaline side of the aqueous solution of a neutral salt to extract the useful substance in a state of being dissolved in the aqueous solution of a neutral salt.

Abstract: A personal care conditioning and/or styling composition for a keratin substrate comprising: (A) at least one conditioning and/or styling ter/tetra polymer obtained by polymerizing: (i) about 50 wt. % to 97 wt. % of at least one cationic or pseudo-cationic monomer selected from the group consisting of diallyl dimethyl ammonium chloride (DADMAC), Hydroxyethyl-pyrrolidone-methacrylate (MO6), and/or Vinylpyrrolidone (VP); (ii) about 1 wt. % to 30 wt. % of at least one anionic monomer selected from the group consisting of (a) acrylic acid (AA), (b) acrylamido methylpropyl sulfonate (AMPS), and/or (c) sodium methyl allyl sulfonate (SMAS); and (iii) about 0.1 wt. % to 20 wt.

Abstract: Disclosed is a method of preparing a hair conditioning composition, wherein the composition comprising: a mono-alkyl amine cationic surfactant; a high melting point fatty compound; an anionic polymer comprising higher % of a vinyl monomer (A) with a carboxyl group; and an aqueous carrier, wherein the method comprises a step: mixing the cationic surfactant, high melting point fatty compound, anionic polymer and aqueous carrier to form an emulsion.

Abstract: The disclosure relates to a cosmetic product, comprising: a) a cosmetic preparation, containing, in relation to its total weight, a1) from about 45 to about 99 wt.-% of at least one polar solvent; a2) from about 0.1 to about 6.0 wt.-% of a cationic polymer; and a3) from about 0.1 to about 12 wt.-% of a non-ionic polymer; b) a device for flash evaporation of the cosmetic preparation a), and to a method using corresponding products and the use of the cosmetic preparation a) as process material in a device for flash evaporation.

Abstract: A personal care conditioning and/or styling composition for a keratin substrate comprising: (i) about 50 wt. % to 95 wt. % of at least one cationic or pseudo-cationic monomer selected from the group consisting of acrylamidopropyl trimethylammonium chloride (APTAC) and/or Vinylpyrrolidone (VP); (ii) about \ wt. % to 30 wt. % of at least one anionic monomer selected from the group consisting of (a) acrylic acid (AA), (b) acrylamido methylpropyl sulfonate (AMPS), and/or (c) sodium methyl allyl sulfonate (SMAS); and (iii) about 0.1 wt. % to 20 wt. % of at least one hydrophobic monomer selected from the group consisting of (a) polyoxyethylene (PEG)-18-behenylether-methacrylate (BEM) (b) Lauryl-ethoxylated-methacrylate (LEM), (c) stearyl acrylate (SA), (d) Stream-10-allyl-ether, (e) Vinylcaprolactam (V-cap), and/or (f) Hydroxyethyl-pyrrolidone-methacrylate (M06). Also described is a process of preparing said polymer, and its method of use.

Abstract: The invention relates to a cosmetic product, comprising a) a cosmetic preparation, including, in relation to its total weight, a1) 65 to 96 wt % of at least one polar solvent; a2) 0.1 to 34 wt % of at least one inorganic salt; b) a device for flash evaporation of the cosmetic preparation a), and to a method using corresponding products and to the use of the cosmetic preparation a) as process material in a device for flash evaporation.

Abstract: Disclosed is a cosmetic product comprising a) a cosmetic preparation containing, in relation to the total weight of the preparation, a1) at least about 88 wt % polar solvent; a2) at least about 0.1 wt % film-forming polymer; b) a device for flash evaporating cosmetic preparation a), the percentage by weight of components a1) and a2) being more than about 92% of the total weight of cosmetic preparation a). Also disclosed is a method using corresponding products and the use of cosmetic preparation a) as a process material in a flash evaporation device.

Abstract: Provided is a gel polish composition comprising (A) a multifunctional silicone urethane (meth)acrylate oligomer, (B) a reactive monomer, and (C) a photoinitiator. The multifunctional silicone urethane (meth)acrylate oligomer (A) consists of siloxane moieties, urethane moieties, and (meth)acrylate moieties. Also provided is a method of using the gel polish composition.

Abstract: The present invention relates to water-dispersable microcapsules comprising an oil phase, e.g. a perfume, containing a photolabile polymer comprising ?-ketoacid or ?-ketoester group capable of generating a gas upon exposure to light. The gas is able to cause an extension or the breaking of the microcapsule allowing the release of the oil phase and thus increasing the long-lastingness of the odor perception. The present invention concerns also the use of said microcapsules in perfumery as well as perfuming compositions or perfumed articles comprising the invention's microcapsules to provide a prolonged release of fragrant molecules.

Abstract: Disclosed herein are compositions and methods for altering the color of hair comprising a first mixture comprising from about 1% to about 50% of at least one starch, from about 1% to about 50% of at least one liquid fatty substance and from about 0.5% to about 40% of at least one silica material, and a second mixture comprising from about 1% to about 40% of at least one oxidizing agent, from about 0.5% to about 30% of at least one acrylic polymer and from about 0.1% to about 10% of at least one chelant compound.

Abstract: The present invention discloses a novel and improved composition and method of preparation of organic topical deodorant. The invention utilizes all readily available natural vegan ingredients for formulation of the deodorant product that results in effective elimination of body odor and retains good structural integrity without drying out or becoming rancid. Present invention achieves the main objectives by creating a unique composition comprised of pure corn starch, unbleached organic all-purpose flour, candelilla wax, virgin coconut oil, raw unfiltered organic apple cider vinegar and an optional fragrance. The disclosed ingredients are cooked in a double boiler at a certain temperature and in a manner that yields the claimed deodorant compound. With the process of this invention coconut oil can be substituted with other natural oils and fragrance can be altogether eliminated from the process without compromising deodorant's efficacy.

Abstract: The present invention relates to pharmaceutical compositions of an non-steroidal anti-inflammatory drug (NSAIDs) such as, aspirin, diclofenac, ibuprofen, ketoprofen, or naproxen, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The compositions, which can be formulated for topical administration, can provide extended release of the NSAIDs. The compositions of the invention are useful, for example, in the prophylactic treatment or treatment and/or reduction of pain, in the prophylactic treatment or treatment of headaches such as migraine headaches and symptoms of migraine headaches, and in the treatment of temporomandibular disorders (TMD).

Abstract: A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).

Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours.

Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.

Abstract: The present invention relates in general to the field of drug delivery systems for treating ocular diseases in animals, and more specifically, to a drug delivery system and method of treating Infectious Bovine Keratoconjunctivitis (“IBK”) in cattle, commonly known as “pinkeye.” The drug delivery system and method may include a contact lens that has been infused with drugs for treating IBK, such as oxytetracycline, penicillin, streptomycin, tetracycline, gentamicin, cloxacillin or combinations thereof. The medicated contact lens may be placed in contact with the cornea and/or conjunctiva of the afflicted eye of the animal. Drugs are released from the medicated contact lens via diffusion into the cornea and/or conjunctiva of the eye. After treatment, the contact lens may harmlessly dissolve in the eye wherein it is washed away via tear secretions.

Abstract: A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: Compositions and methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders are provided. The compositions provided herein are nebulizable compositions comprising quaternary ammonium muscarinic receptor antagonists. The compositions are suitable for direct administration to a patient in need thereof via a nebulizer. Also provided are kits which comprise of the nebulizable composition of the invention in combination with a nebulizer. Also provided is a method of treating, preventing, or amelioration of one or more symptoms of bronchoconstrictive disorders by administering a therapeutically effective amount of the nebulizable composition of the invention via the use of a nebulizer to a patient in need thereof with minimal to no exposure of the nebulizable composition to the body surface of the patient.

Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.

Abstract: The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

Abstract: Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bile acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyric acid-? (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: All natural non-toxic sublingual delivery systems improve absorption and onset profiles for numerous actives, along with bioavailability and pharmacokinetics results that are better than expected for families of moieties compounds and legacy-patented formulations.

Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.